These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 12823591)
1. YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine. Bozdayi AM; Uzunalimoğlu O; Türkyilmaz AR; Aslan N; Sezgin O; Sahin T; Bozdayi G; Cinar K; Pai SB; Pai R; Bozkaya H; Karayalçin S; Yurdaydin C; Schinazi RF J Viral Hepat; 2003 Jul; 10(4):256-65. PubMed ID: 12823591 [TBL] [Abstract][Full Text] [Related]
2. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences. Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034 [TBL] [Abstract][Full Text] [Related]
3. [Identification of factors associated with YMDD mutation in patients with chronic hepatitis B receiving lamivudine treatment]. Cao XX; Li J; Qiu LM; Luo YW; Chen YH; Ran Y Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):641-4. PubMed ID: 19785947 [TBL] [Abstract][Full Text] [Related]
4. Prevelance of common YMDD motif mutations in long term treated chronic HBV infections in a Turkish population. Alagozlu H; Ozdemir O; Koksal B; Yilmaz A; Coskun M Asian Pac J Cancer Prev; 2013; 14(9):5489-94. PubMed ID: 24175847 [TBL] [Abstract][Full Text] [Related]
5. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping. Ohishi W; Shirakawa H; Kawakami Y; Kimura S; Kamiyasu M; Tazuma S; Nakanishi T; Chayama K J Med Virol; 2004 Apr; 72(4):558-65. PubMed ID: 14981758 [TBL] [Abstract][Full Text] [Related]
6. Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment. Wu F; Wu MJ; Zhuge XL; Zhu SM; Zhu B Hepatobiliary Pancreat Dis Int; 2012 Apr; 11(2):172-6. PubMed ID: 22484586 [TBL] [Abstract][Full Text] [Related]
7. [HBV gene variants and polymerse gene mutations in children with chronic hepatitis B in the course of the antiviral therapy]. Góra-Gebka M; Liberek A; Charmuszko U; Sikorska-Wiśniewska G; Szlagatys-Sidorkiewicz A; Korzon M; Bielawski K Med Wieku Rozwoj; 2007; 11(4):367-71. PubMed ID: 18605187 [TBL] [Abstract][Full Text] [Related]
8. The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations. Zhu Y; Curtis M; Borroto-Esoda K Antivir Chem Chemother; 2011 Aug; 22(1):13-22. PubMed ID: 21860069 [TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region. Natsuizaka M; Hige S; Ono Y; Ogawa K; Nakanishi M; Chuma M; Yoshida S; Asaka M J Viral Hepat; 2005 Mar; 12(2):154-9. PubMed ID: 15720530 [TBL] [Abstract][Full Text] [Related]
10. Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy. Lee YS; Chung YH; Kim JA; Kim SE; Shin JW; Kim KM; Lim YS; Park NH; Lee HC; Lee YS; Suh DJ Liver Int; 2009 Apr; 29(4):552-6. PubMed ID: 19323782 [TBL] [Abstract][Full Text] [Related]
11. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B. Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618 [TBL] [Abstract][Full Text] [Related]
12. [Detection and analysis of the new kind of G743C and G743A point mutation of HBV P gene in hepatitis B virus infected patients resistant to lamivudine]. Pan XP; Wo JE; Chen Z; Chen F; Liang WF; Liu KZ Zhonghua Gan Zang Bing Za Zhi; 2003 Oct; 11(10):616-8. PubMed ID: 14572341 [TBL] [Abstract][Full Text] [Related]
13. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011 [TBL] [Abstract][Full Text] [Related]
14. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants. Jardi R; Buti M; Rodriguez-Frias F; Cotrina M; Costa X; Pascual C; Esteban R; Guardia J J Virol Methods; 1999 Dec; 83(1-2):181-7. PubMed ID: 10598095 [TBL] [Abstract][Full Text] [Related]
15. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus. Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816 [TBL] [Abstract][Full Text] [Related]
16. Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy. Lee SH; Kim HS; Byun IS; Jeong SW; Kim SG; Jang JY; Kim YS; Kim BS J Med Virol; 2012 Feb; 84(2):217-22. PubMed ID: 22170540 [TBL] [Abstract][Full Text] [Related]
18. Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy. Zhang X; Liu C; Gong Q; Zhang S; Zhang D; Lu Z; Wang Y J Gastroenterol Hepatol; 2003 Dec; 18(12):1353-7. PubMed ID: 14675262 [TBL] [Abstract][Full Text] [Related]
19. [Efficacy changes of short-term lamivudine therapy for chronic hepatitis B with emergence of YMDD mutation]. Deng H; Lv Y; Fu J Zhonghua Gan Zang Bing Za Zhi; 2004 Jun; 12(6):368-9. PubMed ID: 15225437 [TBL] [Abstract][Full Text] [Related]
20. Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy. Liu KZ; Hou W; Zumbika E; Ni Q J Zhejiang Univ Sci B; 2005 Dec; 6(12):1182-7. PubMed ID: 16358376 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]